Genelux (NASDAQ:GNLX) Rating Increased to Hold at Wall Street Zen

Genelux (NASDAQ:GNLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts also recently issued reports on GNLX. HC Wainwright reaffirmed a “buy” rating on shares of Genelux in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Thursday, January 22nd. Finally, Benchmark lowered their price objective on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research report on Friday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

Genelux Stock Down 5.5%

GNLX opened at $2.40 on Friday. The company has a market capitalization of $91.32 million, a PE ratio of -2.79 and a beta of 0.15. The firm has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $4.14. Genelux has a 52 week low of $1.99 and a 52 week high of $8.53.

Genelux (NASDAQ:GNLX) last posted its earnings results on Thursday, March 19th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.01 million during the quarter. As a group, sell-side analysts expect that Genelux will post -0.88 earnings per share for the current year.

Insiders Place Their Bets

In other Genelux news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total value of $29,000.00. Following the completion of the sale, the director directly owned 482,784 shares in the company, valued at approximately $1,400,073.60. This represents a 2.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.80% of the stock is currently owned by company insiders.

Institutional Trading of Genelux

Institutional investors and hedge funds have recently made changes to their positions in the company. Woodward Diversified Capital LLC lifted its stake in Genelux by 4.8% in the fourth quarter. Woodward Diversified Capital LLC now owns 1,932,711 shares of the company’s stock worth $8,427,000 after acquiring an additional 88,612 shares during the period. Geode Capital Management LLC boosted its stake in shares of Genelux by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 381,407 shares of the company’s stock valued at $1,664,000 after purchasing an additional 27,567 shares in the last quarter. Flputnam Investment Management Co. increased its holdings in Genelux by 708.1% during the third quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock valued at $1,261,000 after buying an additional 263,131 shares during the period. MAI Capital Management increased its holdings in Genelux by 66,161.3% during the second quarter. MAI Capital Management now owns 236,553 shares of the company’s stock valued at $679,000 after buying an additional 236,196 shares during the period. Finally, Global Retirement Partners LLC bought a new position in Genelux in the second quarter worth approximately $656,000. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.